Clinical Trial Update: Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating safety, efficacy and feasibility of long-acting cabotegravir for HIV PrEP in breastfeeding women in Botswana.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Pre-Exposure Prophylaxis (PrEP), Breast Feeding | Phase 4 | Status: ACTIVE_NOT_RECRUITING